Gilead Sciences' abandoned anti-CD47 drug magrolimab was not just ineffective but could potentially be harmful to patients ...
The FDA is joining hands with regulators in Canada and the U.K. on policies to ensure transparency in the development of ...
Cabaletta Bio’s shares tumbled 13% Friday morning as the biotech shared just a crumb of data from two patients in an ...
J.P. Morgan Private Capital has closed an inaugural life sciences fund of more than $500 million, cash that will go toward a ...
Investors celebrating the summer resurgence of biotech IPOs might want to put the champagne back on ice, after Telix ...
Innovent Biologics' bispecific immuno-oncology candidate IBI363 has been linked to a 100% response rate in a small cohort of ...
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...
EnGene is halting work on a cystic fibrosis program to focus resources on moving its lead candidate further into bladder ...
Invizius has completed a first-in-human study of its approach to taming the immune system’s overreaction to dialysis—with the ...
Pfizer’s phase 3 gene therapy trial has failed to demonstrate significant improvement in motor function for boys with ...
Barinthus Biotherapeutics has used positive interim data from a pair of phase 2 trials for its hepatitis B therapy as the ...
With a former Kite Pharma leader at the helm, Santa Ana Bio has unveiled with $168 million and three precision ...